| dc.contributor.author | Dhindsa, Amreek | |
| dc.date.accessioned | 2021-03-31T15:31:03Z | |
| dc.date.available | 2021-03-31T15:31:03Z | |
| dc.date.issued | 2019-02 | |
| dc.identifier.citation | Amreek Dhindsa. Valproate in dementia: time to move on? Commentary on…Cochrane Corner. Advances (2019), vol. 25, 145–149 doi: 10.1192/bja.2019.8 | en |
| dc.identifier.uri | https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/759 | |
| dc.description | The article attached to this record is the Author(s) pre-/post- print version only. NOTE: this is not the version published in BJPsych Advances. Minor changes may have been made for publication.
Eligible users can access the full text via NHS OpenAthens (login required) | |
| dc.description.abstract | Baillon et al ’s Cochrane review included 430 participants with agitation in dementia from five randomised controlled trials. Overall, the reviewers
found that valproate was no better than placebo
for the treatment of agitation in people with dementia; however, the quality of the studies included
was very variable. Adverse effects and events
were higher in the treatment group compared
with the controls, although these finding were
largely based on low-quality data with incomplete
reporting; thus, valproate’s safety profile is of
concern. This review demonstrates that there is
insufficient evidence to change current treatment
guidelines. | en |
| dc.description.uri | https://doi:10.1192/bja.2019.8 | en |
| dc.language.iso | en | en |
| dc.subject | Dementia | en |
| dc.title | Valproate in dementia: time to move on? Commentary on…Cochrane Corner | en |
| dc.type | PrePrint | en |
| dc.contributor.discipline | Medical Trainee | en |
